Targeted Therapy in HR+ HER2− Metastatic Breast Cancer: Current Clinical Trials and Their Implications for CDK4/6 Inhibitor Therapy and beyond Treatment Options

SIMPLE SUMMARY: In the treatment of hormone-receptor positive, HER2 negative metastatic breast cancer, targeted therapy showed improved overall survival and it has become an established treatment within recent years. Some study results conflict with others. As multiple new research articles on this...

Descripción completa

Detalles Bibliográficos
Autores principales: Elfgen, Constanze, Bjelic-Radisic, Vesna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8656925/
https://www.ncbi.nlm.nih.gov/pubmed/34885105
http://dx.doi.org/10.3390/cancers13235994

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8656925/
https://www.ncbi.nlm.nih.gov/pubmed/34885105
http://dx.doi.org/10.3390/cancers13235994

Ejemplares similares